Alzamend Neuro (NASDAQ: ALZN) director gets Series D preferred grant and options
Rhea-AI Filing Summary
Alzamend Neuro director Milton C. Ault III, through Ault Lending, LLC, acquired 7,500 shares of Series D Convertible Preferred Stock on July 31, 2026 as a grant. Each share has a stated value of $1,050.00 and is convertible into Common Stock at a variable Conversion Price; as of August 4, 2026, each was convertible into approximately 1,033.5 Common shares. The filing also lists indirect holdings of several Common Stock purchase warrants and direct stock options for 100,000 shares at a $2.33 exercise price expiring in 2035.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
AULT MILTON C III
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Series D Convertible Preferred Stock F1, F2, F3, F4 | 7,500 | $1,000.00 | $7.50M |
| holding | Common Stock Purchase Warrants F4 | -- | -- | -- |
| holding | Common Stock Purchase Warrants F4 | -- | -- | -- |
| holding | Common Stock Purchase Warrants F4 | -- | -- | -- |
| holding | Common Stock Purchase Warrants F4 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F5 | -- | -- | -- |
Holdings After Transaction:
Series D Convertible Preferred Stock — 7,500 shares (Indirect, By Ault Lending, LLC);
Common Stock Purchase Warrants — 24,322 shares (Indirect, By Ault Lending, LLC);
Stock Options (Right to Buy) — 100,000 shares (Direct)
Footnotes (5)
- F1. Each share of Series D Convertible Preferred Stock has a stated value of $1,050.00 and is convertible into shares of Common Stock at a conversion price equal to the greater of (i) $0.2668 and (ii) 80% of the lowest closing bid price of the Common Stock during the five (5) trading days immediately prior to the date of conversion into conversion shares, but not greater than $2.00 per share (the "Conversion Price"). The Conversion Price is subject to adjustment in the event of issuances of Common Stock at a price per share lower than the Conversion Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events.
- F2. The Series D Convertible Preferred Stock has no expiration date.
- F3. As of August 4, 2026, the Conversion Price was $1.016 per share, so each share of Series D Convertible Preferred Stock is convertible into approximately 1,033.5 shares of Common Stock.
- F4. Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Ault Capital Group, Inc. ("ACG"). ACG is a wholly-owned subsidiary of Hyperscale Data, Inc. ("HSD"). Mr. Ault, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.
- F5. On November 13, 2025, the Board of Directors of the Issuer granted stock options to Mr. Ault to purchase 100,000 shares of Common Stock. Fifty percent (50%) of these options vested and became exercisable on the date that receipt of approval of the option grants by the Issuer's stockholders. Stockholder approval was obtained on April 17, 2026, which was the date that these options vested and became exercisable. The remaining 50% vest in equal monthly increments over 24 months beginning May 17, 2026.
Key Figures
Series D Preferred acquired: 7,500.0000 shares
Transaction price per preferred share: 1000.0000 $/share
Stated value per preferred share: 1,050.00 $/share
+4 more
7 metrics
Series D Preferred acquired
7,500.0000 shares
Grant of Series D Convertible Preferred Stock on 2026-07-31, held indirectly via Ault Lending, LLC
Transaction price per preferred share
1000.0000 $/share
Reported price for the 7,500 Series D Convertible Preferred shares acquired
Stated value per preferred share
1,050.00 $/share
Each Series D Convertible Preferred share has a stated value of $1,050.00
Conversion Price as of 2026-08-04
1.016 $/share
Conversion Price for Common Stock under the Series D Convertible Preferred on August 4, 2026
Common shares per preferred share
1,033.5 shares
Approximate Common Stock each Series D Convertible Preferred share was convertible into as of 2026-08-04
Warrant underlying shares (largest series)
13,556.0000 shares
Common Stock underlying indirect warrants with a 108.0000 exercise price expiring 2029-08-01
Stock options held
100,000.0000 shares
Underlying Common Stock for options held directly by Mr. Ault at a 2.3300 exercise price expiring 2035-11-12
Key Terms
Series D Convertible Preferred Stock, Conversion Price, Common Stock Purchase Warrants, vest, +1 more
5 terms
Series D Convertible Preferred Stock financial
"acquired 7,500 shares of Series D Convertible Preferred Stock on July 31, 2026"
Series D convertible preferred stock is a class of shares issued in a later-stage funding round that gives holders priority over common shareholders for payouts and often a fixed dividend, while including an option to convert those shares into common stock. It matters to investors because it affects who gets paid first if a company is sold or liquidates and can change ownership stakes and voting power when converted, similar to holding a safer ticket that can be exchanged for regular tickets later.
Conversion Price financial
"convertible into shares of Common Stock at a conversion price equal to the greater of"
The conversion price is the fixed price at which a convertible security, like a bond or preferred stock, can be exchanged for shares of common stock. It acts like a set rate that determines how many shares an investor can receive if they choose to convert their investment. This helps investors understand the value and potential benefits of converting their securities into company shares.
Common Stock Purchase Warrants financial
"Common Stock Purchase Warrants with exercise prices of $4,050.00 and $108.00"
Common stock purchase warrants are tradable instruments that give the holder the right to buy a company’s common shares at a set price before a specified date, like a coupon that lets you purchase stock later at a fixed rate. They matter to investors because they offer a way to gain future upside if the stock rises, but when exercised they increase the number of shares outstanding and can reduce existing shareholders’ ownership and earnings per share.
vest financial
"The remaining 50% vest in equal monthly increments over 24 months"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
Section 16 of the Exchange Act regulatory
"For purposes of Section 16 of the Exchange Act, each of HSD, ACG and Ault Lending"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Milton C. Ault III report in his ALZN Form 4 filing?
He reported acquiring 7,500 shares of Series D Convertible Preferred Stock indirectly through Ault Lending, LLC. The filing also discloses indirect holdings of Common Stock purchase warrants and direct stock options for 100,000 ALZN shares at a $2.33 exercise price expiring in 2035.
What are the conversion terms of ALZN's Series D Convertible Preferred Stock?
Each preferred share converts into Common Stock at the greater of $0.2668 and 80% of the lowest closing bid over five trading days, capped at $2.00. As of August 4, 2026, the Conversion Price was $1.016, making each share convertible into about 1,033.5 Common shares.
What warrants linked to ALZN Common Stock are disclosed in this Form 4?
Indirectly through Ault Lending, LLC, the filing lists Common Stock purchase warrants with exercise prices of $4,050.00 and $108.00, covering 988, 13,556, 8,667 and 1,111 underlying Common shares, with expirations between 2027 and 2029.
What stock options in ALZN does Milton C. Ault III hold according to this filing?
He holds stock options for 100,000 ALZN Common shares at a $2.33 exercise price, expiring on November 12, 2035. Granted November 13, 2025, half vested upon stockholder approval on April 17, 2026, with the remainder vesting monthly over 24 months beginning May 17, 2026.